Table 1.
Name | Cancer types | Applications | Definition | Criteria | Advantages | Disadvantages | Reference (year) |
---|---|---|---|---|---|---|---|
RECIST | Solid tumors | Tumor therapeutics | PD | ≥20% increase in size | More accurate assessments for treatment response than before | HPD undefined | (12) (2001) |
RECIST 1.1 | Solid tumors | Tumor therapeutics | PD | ≥20% increase in the sum of diameters of target lesions (new lesions are also considered progression) | Improvement in dimension assessments; newer imaging technologies; new lesions are considered | HPD undefined | (11) (2009) |
irRECIST | Solid tumors | Antitumor immunotherapy | irPD | ≥25% increase in tumor burden, repeatable | Specific for immunotherapy | HPD undefined | (13) (2009) |
TGRR | Solid tumors | PD-1/PD-L1 inhibitors | HPD | TGRR ≥2 | First introduced HPD definition | Pre-ICI treatments details are necessary; reference period is limited | (16) (2017) |
TGKR | R/M HNSCC | PD-1/PD-L1 inhibitors | HPD | TGKR ≥2 | Pseudoprogression and HPD can be distinguished; simpler calculation | Pre-ICI treatments details are necessary | (17) (2017) |
Kato et al. criteria | Multiple types of solid tumors | Immunotherapy agents | HPD | TTF <2 months; 50% increase in tumor burden; >2-fold change in progression rate | Less time for HPD recognition | Clinical status changes are ignored | (18) (2017) |
Lo Russo et al. criteria | Multiple types of solid tumors | ICIs | HPD, ≥3 criteria | TTF <2 months; 50% increase in tumor lesions; ≥ 2 new lesions; spread of disease; clinical deterioration by ECOG | Applicable for first-line treatment with ICIs | Higher false positive | (19) (2019) |
PD, progressive disease; R/M HNSCC, recurrent/metastatic head and neck squamous cell carcinoma; TGKR, ratio of the rate of tumor growth on ICI treatment to that before ICI treatment.